Maintenance Ruxolitinib
Phase II Study of Maintenance Ruxolitinib After Allogeneic Stem Cell Transplantation for Older Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) in Complete Remission
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 2
- Enrollment
- 64 patients (estimated)
- Sponsors
- Massachusetts General Hospital
- Collaborators
- Washington University School of Medicine, Ohio State University Comprehensive Cancer Center, Medical College of Wisconsin, Vanderbilt University Medical Center
- Tags
- JAK2 Inhibitor, Tyrosine Kinase (TK) Inhibitor, Maintenance, Post-Allogeneic Stem Cell Transplant
- Trial Type
- Treatment
- Last Update
- 1 week ago
- SparkCures ID
- 1671
- NCT Identifier
- NCT03286530
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print this trial to share with your doctor.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.